Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rangering i aksjer #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aksjekurs
$0.11725176
Sist synkronisert: 2025-07-14
Markedsverdi
$481.50K
Endring (1 dag)
-0.20%
Endring (1 år)
0.00%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Kategori

EPS for PHAXIAM Therapeutics S.A. (PHXM)
EPS per June 2024 TTM: $-4.23
Ifølge de siste økonomiske rapportene og aksjekursen til PHAXIAM Therapeutics S.A. er selskapets nåværende EPS (TTM) $-4.23. Ved slutten av 2022 hadde selskapet en EPS på $-0.07, en nedgang sammenlignet med EPS-en i 2021 som var $-23.87.
EPS-historikk for PHAXIAM Therapeutics S.A. fra 2016 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) $-4.23 -23.50%
2023 $-5.53 7,492.45%
2022 $-0.07 -99.69%
2021 $-23.87 -46.82%
2020 $-44.88 23.87%
2019 $-36.23 60.03%
2018 $-22.64 -30.76%
2017 $-32.70 21.96%
2016 $-26.81 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -509.44%
US
$27.74 -755.76%
NL
- -
CH
- -
KR
$13.70 -423.86%
BE